Program
REGEND001
A development code. Also written as “REGEND001 cell therapy”.
Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Idiopathic Pulmonary Fibrosis, led by Regend Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regend Therapeutics | 41 open or running | phase 3since Sep 14, 2026 | Nov 2, 2022 | Sep 2028phase 3 · NCT07828353 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 2, 2022First study: phase 2 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT05638776 · 58 enrolled · China
- Nov 15, 2022Phase 1 study in Idiopathic Pulmonary FibrosisNCT05657184 · 12 enrolled · China
- Sep 17, 2023Phase 2 study in Idiopathic Pulmonary FibrosisNCT06081621 · 23 enrolled · China
- Sep 14, 2026Phase 3 study in Pulmonary Disease, Chronic ObstructivePhase 3 reachedNCT07828353 · 102 planned · China
Ahead
- Sep 2028Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07828353
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07828353Pulmonary Disease, Chronic Obstructive · China | 3 | Not yet recruiting | Sep 2028 | 102 |
| NCT06081621Idiopathic Pulmonary Fibrosis · China | 2 | Completed | Mar 14, 2025 | 23 |
| NCT05657184Idiopathic Pulmonary Fibrosis · China | 1 | Completed | Jun 9, 2023 | 12 |
| NCT05638776Pulmonary Disease, Chronic Obstructive · China | 2 | Completed | Jul 9, 2025 | 58 |
How it is read
Names in the registry
- “REGEND001”, 3 entries
- “REGEND001 cell therapy”, 1 entry
Codes read as this program: REGEND001.
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 2 studies
- Idiopathic Pulmonary Fibrosis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.